Philip Ashton-Rickardt grew up in a working-class family in the UK with no clear path to an academic career, yet built a distinguished tenure at the University of Chicago and Imperial College London before pivoting to biotech entrepreneurship. Now, as Managing Director and Chief Scientific Officer at BE Therapeutics, he is developing proto-cortex implants designed to physically replace damaged brain tissue in stroke and traumatic brain injury patients.
The brain does not forgive easily. When stroke or trauma destroys tissue, the loss is typically permanent. Neurons do not regenerate in any meaningful way. The scaffolding collapses. What remains is deficit: lost speech, lost movement, lost memory. For decades, the best medicine could offer was management, rehabilitation, adaptation. Not restoration.
Philip Ashton-Rickardt is working to change that premise. As Managing Director and Chief Scientific Officer at BE Therapeutics, a seed-stage biotechnology company based between New York and Boston, he is leading the development of proto-cortex implants: engineered tissue constructs combining iPSC-derived neurons, glia, and vascular cells with proprietary extracellular matrix biogels. The goal is not to slow degeneration or mask symptoms, but to replace what has been lost. Validation in animal models is underway, with a development path aimed at treating chronic stroke patients within three years.
The work represents a departure from traditional pharmacological interventions. Where drugs modulate, and gene therapies correct, tissue engineering attempts to rebuild. It is an ambitious proposition, both scientifically and operationally, and it draws on more than 30 years of experience Ashton-Rickardt has accumulated across two continents, multiple institutions, and the often unforgiving terrain between academic science and commercial biotechnology.
The Long Apprenticeship
Ashton-Rickardt did not arrive at this point through privilege or clear institutional pathways. He grew up in the UK in a working-class family, with no familial precedent for higher education. The route from that origin to a PhD in Molecular Immunology from the University of Edinburgh, completed in 1988, was one he had to map himself. He has described this early self-reliance as formative, a kind of preparation for the uncertainties of starting companies later in life.
After his doctorate, he moved to MIT for postdoctoral training, then joined the University of Chicago in 1995 as a faculty member. He was awarded tenure in 2001, a significant marker of institutional confidence. During his time in Chicago, he also directed the Gwen Knapp Center ES Cell and Transgenic Mouse Facility, a role that placed him at the operational intersection of cutting-edge research and institutional infrastructure. In 1999, President William Clinton awarded him the Presidential Early Career Award for Scientists and Engineers, one of the highest honors for young researchers in the United States.
In 2006, he moved to Imperial College London, where he became Professor and Head of the Department of Immunology. He remained there for more than a decade, navigating the complexities of academic leadership, grant funding, and collaborative science. He served on numerous panels and advisory bodies, including the Medical Research Council, the Israel Science Foundation, and the NIH Immunobiology Study Section. These were years of deep immersion in the mechanics of molecular immunology, T cell biology, and the regulatory systems that govern immune tolerance and inflammation.
The Pivot to Industry
In November 2017, Ashton-Rickardt left Imperial College and returned to the Greater Boston area to found Smith Therapeutics. The company focused on CAR-Treg cell therapies for neurodegenerative diseases, including ALS and multiple sclerosis. It was a sharp pivot from the relative stability of tenured academic life to the high-stakes uncertainty of biotech entrepreneurship. Smith Therapeutics was acquired by AZTherapies in 2019, and Ashton-Rickardt joined the acquiring company as Senior Vice President for Immunology, a position he held until mid-2021.
Later that year, he became Chief Scientific Officer at Sigilon Therapeutics, a Cambridge-based company developing shielded living cell products designed to protect therapeutic cells from immune attack. Sigilon’s platform aimed to address a persistent challenge in cell therapy: how to deliver functional cells into the body without triggering rejection or requiring chronic immunosuppression. Ashton-Rickardt led the company’s research and development efforts through a period of clinical advancement and strategic repositioning. In 2023, Eli Lilly acquired Sigilon. He remained with the organization through the integration, stepping down in March 2024.
The following summer, he served as a Senior Scientific Advisor at Flagship Pioneering, the venture creation firm known for its model of internally incubating biotech companies before spinning them out. The role was brief but strategically positioned, offering insight into the earliest stages of company formation and scientific thesis development. By March 2024, he had also co-founded Halyard Therapeutics, where he serves as President, Chief Scientific Officer, and Founder. Halyard is focused on engineered cell therapies for neurodegenerative diseases, continuing a thematic thread that runs through much of his post-academic career.
Engineering the Proto-Cortex
BE Therapeutics, where Ashton-Rickardt began as Managing Director and CSO in June 2025, is working at the edge of what cell engineering can accomplish. The company describes its proto-cortex technology as a method to physically replace damaged brain tissue, not merely to protect remaining neurons or slow disease progression. The implants are constructed from induced pluripotent stem cell-derived neurons, glial cells, and vascular cells, embedded in proprietary biogels that mimic the extracellular matrix of brain tissue.
The approach is intended for conditions where tissue loss is the central problem: stroke, traumatic brain injury, and potentially certain neurodegenerative diseases. Animal studies are in progress. If the technology proves viable in preclinical models, the company aims to advance toward human trials within a few years, beginning with chronic stroke patients whose brain tissue has been irreversibly damaged.
The scientific challenges are considerable. The brain is not a passive recipient of grafted tissue. Integration, vascularization, immune tolerance, functional connectivity—all must be addressed for the implants to do more than occupy space. Ashton-Rickardt’s background in immunology and T cell regulation is directly relevant here. His work has long centered on how the immune system distinguishes self from non-self, and how that distinction can be managed or manipulated in therapeutic contexts.
The Shape of a Career
Ashton-Rickardt’s trajectory reflects a kind of disciplined opportunism. He built credibility in academic immunology over two decades, earning tenure, federal research awards, and international appointments. He then shifted into industry at a moment when his expertise in immune regulation and cell biology aligned with emerging opportunities in cell and gene therapy. Each subsequent role—founder, executive, advisor—has been in organizations developing engineered cellular products for diseases where traditional therapeutics have limited impact.
The transition from academia to industry is not uncommon, but it is rarely smooth. Academic success does not automatically translate into commercial execution. Ashton-Rickardt has noted that his early experience of charting his own course through college and graduate school prepared him for the uncertainties of company building. There is a thematic consistency in his reflections: the value of learning continuously, the importance of setting personal standards, the usefulness of looking back to measure progress.
He has also emphasized authenticity as a guiding principle, both in leadership and in science. In a field where hype often outpaces data, and where investor expectations can distort research priorities, maintaining a clear sense of what the science actually supports is not a trivial discipline.
What Comes Next for Philip Ashton-Rickardt
BE Therapeutics is still in its early stages. The proto-cortex platform is unproven in humans. The regulatory pathway for tissue implants in the brain will be complex. The science, while grounded in established principles of stem cell biology and tissue engineering, is far from mature. But the potential clinical impact is significant. If the technology works, it could represent a fundamental shift in how medicine approaches brain injury and degeneration.
Ashton-Rickardt continues to lead both BE Therapeutics and Halyard Therapeutics, balancing scientific oversight with operational responsibilities. His role combines research strategy, team building, and the translation of laboratory findings into developable products. It is a role that requires fluency in multiple domains: immunology, neuroscience, regulatory science, and business strategy.
The next few years will be critical. Preclinical data will either support or undermine the core thesis. Early human studies, if they occur, will test whether engineered brain tissue can integrate, survive, and function in patients. The stakes are high, both for the patients who might one day benefit and for the scientific credibility of tissue replacement as a therapeutic modality. Ashton-Rickardt, drawing on decades of experience and a career built on reinvention, is positioned to see the work through.
